Feb 18 (Reuters) - Galectin Therapeutics Inc GALT.O:
GALECTIN THERAPEUTICS INC - REPORTS SIGNIFICANT REDUCTION IN NEW VARICES WITH BELAPECTIN
GALECTIN THERAPEUTICS INC - NAVIGATE TRIAL SHOWS 68.1% REDUCTION IN NEW VARICES WITH BELAPECTIN
GALECTIN THERAPEUTICS INC - ADDITIONAL DATA OF NAVIGATE TRIAL EXPECTED BY END OF Q1 2025
Source text: [ID:n0001140361-25-004971]
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.